Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Sharp & Dohme LLC | 1,934 |
| 2 | Bristol Myers Squibb Co | 1,592 |
| 3 | Takeda Pharmaceutical Co Ltd | 1,494 |
| 4 | Novartis AG | 1,218 |
| 5 | Boehringer Ingelheim International GmbH | 741 |
| 6 | Gilead Sciences Inc | 519 |
| 7 | AstraZeneca AB | 494 |
| 8 | Organon Pharma UK Ltd | 456 |
| 9 | F Hoffmann La Roche AG | 374 |
| 10 | Bayer Pharma AG | 354 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 30,210 |
| 2 | A61K | Medicinal preparations | 25,842 |
| 3 | C07D | Heterocyclic compounds | 17,297 |
| 4 | C07K | Peptides | 3,476 |
| 5 | C07C | Acyclic and carbocyclic compounds | 2,747 |
| 6 | Y02A | Climate change adaptation | 1,909 |
| 7 | C12N | Microorganisms, enzymes | 1,564 |
| 8 | G01N | Investigating / analysing materials | 1,539 |
| 9 | C07B | General methods of organic chemistry | 1,342 |
| 10 | C07F | Organometallic compounds | 1,112 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Avapro dispersible tablet and preparation method thereof | 2010 | BEIJING YILING BIOENGINEERING CO., LTD. | 8 |
| Avapro dispersible tablet and preparation method thereof | 2013 | BEIJING YILING BIOLOGICAL ENGINEERING TECHNOLOGY CO.,LTD. | 0 |
| Aprovel | 1998 | SANOFI | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Blood Pressure and Hypertension Studies | 19 |
| 2 | Renin-Angiotensin System Studies | 9 |
| 3 | Heart Failure Treatment and Management | 6 |
| 4 | Renal Diseases and Glomerulopathies | 5 |
| 5 | Atrial Fibrillation Management and Outcomes | 4 |
| 6 | Receptor Mechanisms and Signaling | 4 |
| 7 | Cardiovascular Health and Disease Prevention | 3 |
| 8 | Drug-Induced Hepatotoxicity and Protection | 2 |
| 9 | Hormonal Regulation and Hypertension | 2 |
| 10 | Inflammatory mediators and NSAID effects | 2 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Andrew Palmer | Center for Outcomes Research and Clinical Epidemiology | 16 |
| 2 | Thomas Kahan | Karolinska Institutet | 15 |
| 3 | A.H. Jan Danser | Erasmus University Rotterdam | 14 |
| 4 | Hans‐Henrik Parving | Aarhus University | 14 |
| 5 | Peter Bramlage | Technische Universität Dresden | 14 |
| 6 | Karin Malmqvist | Karolinska Institutet | 13 |
| 7 | Agata Ptaszynska | Bristol-Myers Squibb (United States) | 12 |
| 8 | John J.V. McMurray | University of Glasgow | 12 |
| 9 | Michel Burnier | Hôpital Orthopédique de la Suisse Romande | 12 |
| 10 | Michael R. Zile | Medical University of South Carolina | 9 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes | 2001 | 6022 | Blood Pressure and Hypertension Studies |
| The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes | 2001 | 2894 | Blood Pressure and Hypertension Studies |
| [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. | 2001 | 2531 | Blood Pressure and Hypertension Studies |
| Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction | 2008 | 1955 | Atrial Fibrillation Management and Outcomes |
| Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study | 2011 | 1434 | Atrial Fibrillation Management and Outcomes |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Avapro?
What are the major pharmaceutical assignees with patent portfolios related to this compound?
What are the main research topics associated with Avapro in the scientific literature?
Which patent classifications dominate the intellectual property landscape for this compound?
What is the recent patent and publication activity trend for this compound?